Ajanta Pharma launches generic asthma drug in US market
New Delhi, Nov 16 : Ajanta Pharma today said it has launched generic version of Singulair granules, used in the treatment of asthma, in the US market.The company in a filing to BSE said Ajanta Pharma US Inc has launched montelucast sodium granules, a generic version of Merck & Co, Inc's Singulair granules, in the US market.The granules have been launched in cartons containing 30...
Login or Register to read the full article
New Delhi, Nov 16 : Ajanta Pharma today said it has launched generic version of Singulair granules, used in the treatment of asthma, in the US market.
The company in a filing to BSE said Ajanta Pharma US Inc has launched montelucast sodium granules, a generic version of Merck & Co, Inc's Singulair granules, in the US market.
The granules have been launched in cartons containing 30 individual sachets.
"The approval and launch of the granules are part of an ever growing portfolio that Ajanta Pharma has developed for the US market", the drug firm said.
Ajanta has so far received five abbreviated new drug application (ANDA) approvals from the US Food and Drug Administration (USFDA).
An additional 19 ANDAs are pending approval from the US FDA.
Shares of Ajanta Pharma today ended at Rs 1,334.55 apiece on the BSE, down 4.02 per cent from previous close.
The company in a filing to BSE said Ajanta Pharma US Inc has launched montelucast sodium granules, a generic version of Merck & Co, Inc's Singulair granules, in the US market.
The granules have been launched in cartons containing 30 individual sachets.
"The approval and launch of the granules are part of an ever growing portfolio that Ajanta Pharma has developed for the US market", the drug firm said.
Ajanta has so far received five abbreviated new drug application (ANDA) approvals from the US Food and Drug Administration (USFDA).
An additional 19 ANDAs are pending approval from the US FDA.
Shares of Ajanta Pharma today ended at Rs 1,334.55 apiece on the BSE, down 4.02 per cent from previous close.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd